N
Neurocrine Biosciences, Inc. (NBIX)
NMS – Real vaqt narxi. Valyuta: USD
155.80
+5.21 (3.46%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
155.80
+5.21 (3.46%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Neurocrine Biosciences, Inc. Qo'shma Shtatlar va xalqaro miqyosda nevrologik, psixiatrik, endokrin va immunologik kasalliklar uchun farmatsevtika mahsulotlarini ishlab chiqaradi, ishlab chiqadi va tijoratlashtiradi. Mahsulotlariga guntiyaning kechki diskenziyasi va Xantingtonda kasalligi bilan bog'liq xoreya uchun INGREZZA; endometriozni davolash uchun Orilissa planshetlari; bachadon miomalarini davolash uchun Oriahnn kapsulalari; va tug'ma buyrak usti bezi giperplaziyasini davolash uchun CRENESSITY kiradi, shuningdek, ALKINDI va Efmody nomlari ostida mahsulotlar taklif etadi. Klinik rivojlanish bosqichidagi mahsulot nomzodlari orasida harakat buzilishlarini davolash uchun NBI-1076986; katta depressiv buzilishlarni davolashda muvaffaqiyatsiz javob uchun Osavampator; shizofreniya va bipolyar maniyni davolash uchun NBI-1117568; Altsgeymer kasalligini davolash uchun NBI-1117567; epilepsiyani davolash uchun NBI 921355; tug'ma buyrak usti bezi giperplaziyasini davolash uchun NBIP-01435; semirish va unga bog'liq metabolik kasalliklarni davolash uchun NBIP-2118; va katta depressiv buzilishlarni davolash uchun NBI-1070770; hamda nevropsixiatrik va nevrologik sharoitlarni davolash uchun NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675 va NBI-1065890 kiradi. Mashina Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; va AbbVie Inc. bilan litsenziya va hamkorlik shartnomalariga ega. Kompaniya 1992 yilda tashkil etilgan va San-Diego, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Eiry Wyn Roberts M.D. | Strategic Advisor |
| Dr. Jude Onyia Ph.D. | Chief Scientific Officer |
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder of Neurocrine |
| Dr. Sanjay Keswani B.Sc., M.D., MBBS | Chief Medical Officer |
| Dr. Wylie W. Vale Ph.D. | Co-Founder |
| Mr. Eric S. Benevich | Chief Commercial Officer |
| Mr. Kyle W. Gano Ph.D. | President, CEO & Director |
| Mr. Lewis Choi | Chief Information Officer |
| Mr. Matthew C. Abernethy CPA | Chief Financial Officer |
| Mr. Todd Tushla | Vice President of Investor Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-05 | 10-Q | nbix-20260331.htm |
| 2026-04-29 | SC TO-T/A | d106727dsctota.htm |
| 2026-04-28 | SC TO-T/A | d142818dsctota.htm |
| 2026-04-20 | SC TO-T | d140647dsctot.htm |
| 2026-04-15 | DEFA14A | a2026additionalmaterials.htm |
| 2026-04-15 | DEF 14A | nbix-20260415.htm |
| 2026-04-07 | SC TO-C | d91998dsctoc.htm |
| 2026-04-06 | SC TO-C | d124039dsctoc.htm |
| 2026-04-06 | 8-K | d110123d8k.htm |
| 2026-02-11 | 8-K | nbix-20260211.htm |